Huons Group participates ‘Dubai Derma 2025’ for efforts to maximize sales

- Humedix signs HA Filler supply contract… “Expansion to the Middle East” -

- Huons Meditech’s ‘Dermashine Pro’ & Huons Biopharma’s ‘Hutox’ attract attention –

▲ Humedix, Huons Meditech and Huons Biopharma of Huons Group attended Dubai World Dermatology and Laser Conference and Exhibition, ‘Dubai Derma 2025’. The photo shows visitors examining products at Huons Group’s exhibition booth.

Huons Group participated in a dermatology exhibition in Dubai, Middle East, unveiling Group Companies’ innovative products and cutting-edge technologies to enhance global competitiveness.

On April 17, Humedix (CEO Kang Min-jong), Huons Meditech (CEO Lee Jin-suk), Huons Biopharma (CEO Kim Yeong-mok) announced that the Group Companies participated this year’s Dubai World Dermatology and Laser Conference & Exhibition, Dubai Derma 2025, held this week from April 14 - 16 at Dubai World Trade Center, Dubai, United Arab Emirates.

Dubai Derma 2025 is the 24^th edition of the largest derma professional gathering in the Middle East and North Africa (MENA). The event featured participation of leading companies and experts in the field of medical devices, aesthetic, and cosmeceutical (a combination of cosmetics and pharmaceuticals) and conferences to promote the development of the skin care industry in the Middle East.

At the exhibition, Humedix signed a supply contract for its famous hyaluronic acid (HA) filler Elravie, in Saudi Arabia, Lebanon, and Syria, establishing a bridgehead for expanding into the Middle Eastern market.

Elravie Premier is a filler that uses Humedix’s proprietary technology to maintain the viscosity of HA. Elravie received product approval from Korea, the European Union (CE), China (NMPA, National Medical Products Administration), and Russia (RZN, Federal Service for Surveillance in Healthcare). Elravie is currently being exported to 19 countries, including China and Brazil.

CEO of Humedix, Kang Min-jong said “Elravie has already earned deep trust from Middle Eastern buyers based on its excellent efficacy and safety. We plan to actively expand into the Middle Eastern market by advancing into Saudi Arabia, an important market in the Middle East.”

Huons Meditech received spotlight on ‘Dermashine Pro’ from buyers at the exhibition. ‘Dermashine Pro’ is an automatic mesotherapy injector using automatic pressure detection system, which injects high-molecular-weight hyaluronic acid to the entire face. Huons Meditech recorded the cumulative sales of 20,000 units of the ‘Dermashine’ product series by the end of 2024.

CEO of Huons Meditech, Lee Jin-suk said “At Dubai Derma 2025, Huons Meditech has opened many new business opportunities and we plan to expand into the global market. We will further strengthen our position in the global medical device market by enhancing overseas marketing.”

Huons Biopharma attracted much attention from visitors on Company’s botulinum toxin products and proprietary technology at the exhibition. Huons BioPharma obtained product approval in 15 countries including Russia, Southeast Asia (Thailand, etc.), and the Middle East (Iraq, etc.) for botulinum toxin, and is in the process of obtaining product approval in China as well.

According to a Company official, “Taking advantage of our participation in Dubai Derma 2025, we will continue to promote competitive advantage of our product and secure strategic partnership to expand our products into the Middle East.”